RxSight (RXST) Set to Announce Earnings on Monday

RxSight (NASDAQ:RXSTGet Rating) will post its quarterly earnings results after the market closes on Monday, August 8th. Analysts expect RxSight to post earnings of ($0.68) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

RxSight (NASDAQ:RXSTGet Rating) last posted its earnings results on Thursday, May 5th. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.02. The company had revenue of $8.94 million during the quarter, compared to analyst estimates of $7.73 million. RxSight had a negative return on equity of 251.55% and a negative net margin of 212.04%. On average, analysts expect RxSight to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

RxSight Stock Up 4.2 %

NASDAQ:RXST opened at $15.70 on Friday. RxSight has a 52 week low of $8.80 and a 52 week high of $16.99. The company has a current ratio of 15.12, a quick ratio of 14.32 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $431.83 million and a PE ratio of -2.89. The stock has a 50 day moving average of $14.49 and a 200-day moving average of $13.11.

Institutional Investors Weigh In On RxSight

A number of institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System lifted its holdings in shares of RxSight by 73.2% during the 1st quarter. California State Teachers Retirement System now owns 7,467 shares of the company’s stock valued at $92,000 after buying an additional 3,156 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in RxSight by 52.2% during the 1st quarter. JPMorgan Chase & Co. now owns 8,227 shares of the company’s stock valued at $102,000 after purchasing an additional 2,820 shares during the last quarter. American International Group Inc. raised its stake in shares of RxSight by 96.9% in the first quarter. American International Group Inc. now owns 8,709 shares of the company’s stock worth $108,000 after acquiring an additional 4,285 shares during the last quarter. Rhumbline Advisers bought a new position in shares of RxSight in the first quarter worth about $153,000. Finally, SVB Wealth LLC bought a new position in shares of RxSight in the first quarter worth about $251,000. 31.57% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC started coverage on RxSight in a report on Friday, April 8th. They set a “buy” rating and a $18.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $19.83.

RxSight Company Profile

(Get Rating)

RxSight, Inc, a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.

Featured Articles

Want More Great Investing Ideas?

Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.